The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid growing optimism in the European healthcare sector, Jefferies has reiterated its 'Buy' rating on Sanofi (SAN) and maintained its price target at EUR 100. This recommendation is bolstered by recent regulatory approvals for the company's therapies and ongoing progress in its product development pipeline. According to reports, the decision to maintain a positive outlook reflects analyst confidence in Sanofi's ability to drive sustainable growth through its innovative drug portfolio.
This rating comes as major pharmaceutical firms face intense competition, with market data showing relatively stable performance from peers such as Roche and Novartis. Looking at historical financial performance, Sanofi reported a growth of approximately 5.6% in specialty care sales during Q1 2024 according to company earnings reports, supporting the valuation case made by Jefferies. Markets are also weighing the impact of European monetary policy on sector financing costs, particularly following Lagarde's speech on May 28, 2024, per economic calendar data.
Sign in to access this content
Sign InInvestors should monitor current price levels, as SAN.PA closed at EUR 89.45 (close June 3, 2026) according to market data. On the economic front, French inflation data, which reached 2.4% YoY on May 29, 2024, may influence investor sentiment in the local market. Furthermore, the ECB Monetary Policy Meeting Accounts will be a key catalyst for traders to assess future interest rate trends and their impact on Paris-listed growth stocks.